In addition, Pasithea has completed initial dosing of three patients in Cohort 4A (15mg capsule). Patient recruitment for Cohort 4B is ongoing (4mg tablet). The Company plans to present interim safety ...
New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledge ...
PHOENIX, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Solera Health, the premier technology platform for connecting people seamlessly and easily to health solutions that work, today announced $40 million in new ...
Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease ...
KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.
Minimally Invasive Surgical Access Systems Require Dedicated Instruments to Transform Neurosurgery. LOS GATOS, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- E8, Inc. unveiled its next ...
It is my pleasure to welcome Nishant to the Jeune team,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech and Chairman of Jeune Aesthetics. “As a seasoned finance executive and ...
By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...
The full research publication is available at: A healthy live birth after preimplantation genetic testing for structural rearrangements and Bionano revealed exceptionally complex chromosome ...
I want to take this opportunity to thank you for your continued trust and support in Nexalin Technology. Our progress over the past year reflects our commitment to addressing the global mental health ...
Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures ...
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical ...